Dafinchi
Medpace Q1 2026 Cancellations and Future Outlook Analysis
Medpace’s Q1 2026 report reveals elevated cancellations affecting backlog and near-term revenue, yet the company maintains guidance amid ongoing industry volatility.
Read post
Detailed company information
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 23, 2026
Earnings Transcript for 2026 - Q1Released: Apr 23, 2026
Earnings Transcript for 2025 - Q4Released: Feb 10, 2026
Earnings Transcript for 2025 - Q3Released: Oct 23, 2025
Earnings Transcript for 2025 - Q2Released: Jul 22, 2025
Earnings Transcript for 2025 - Q1Released: Apr 22, 2025
Earnings Transcript for 2024 - Q4Released: Feb 11, 2025
Earnings Transcript for 2024 - Q3Released: Oct 22, 2024
Earnings Transcript for 2024 - Q2Released: Jul 23, 2024
Earnings Transcript for 2024 - Q1Released: Apr 23, 2024
Earnings Transcript for 2023 - Q4Released: Feb 13, 2024
Earnings Transcript for 2023 - Q3Released: Oct 24, 2023
Earnings Transcript for 2023 - Q2Released: Jul 25, 2023
Earnings Transcript for 2023 - Q1Released: Apr 25, 2023
Earnings Transcript for 2022 - Q4Released: Feb 14, 2023
Earnings Transcript for 2022 - Q3Released: Oct 25, 2022
Earnings Transcript for 2022 - Q2Released: Jul 26, 2022
Earnings Transcript for 2022 - Q1Released: Apr 26, 2022
Earnings Transcript for 2021 - Q4Released: Feb 15, 2022
Earnings Transcript for 2021 - Q3Released: Oct 26, 2021
Earnings Transcript for 2021 - Q2Released: Jul 27, 2021
Earnings Transcript for 2021 - Q1Released: Apr 27, 2021
Earnings Transcript for 2020 - Q4Released: Feb 16, 2021
Earnings Transcript for 2020 - Q3Released: Oct 27, 2020
TWST Twist Bioscience Corporation
Medpace’s Q1 2026 report reveals elevated cancellations affecting backlog and near-term revenue, yet the company maintains guidance amid ongoing industry volatility.
Read postQ1 2026 cancellations at Medpace present a near-term challenge impacting backlog conversion and book-to-bill ratios, but with current backlog support and strategic management, guidance remains achievable for the year.
Read post